| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
Steglatro is owned by Msd Sub Merck.
Steglatro contains Ertugliflozin.
Steglatro has a total of 1 drug patent out of which 0 drug patents have expired.
Steglatro was authorised for market use on 19 December, 2017.
Steglatro is available in tablet;oral dosage forms.
Steglatro can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Drug patent challenges can be filed against Steglatro from 19 December, 2021.
The generics of Steglatro are possible to be released after 13 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLATRO family patents
